AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14649479
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of minimal residual disease (MRD) by identifying clone-specific T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements
Trial: 14649479
Drug: Standardized tools
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized tools for treatment response evaluation
Trial: 9062865
Drug: Melatonin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (1 mg)
Trial: 3283229
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (1400 mg/day: 400‐mg calcium diet plus two 500‐mg calcium tablets/day)
Trial: 3283229
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium intake (400 mg calcium diet plus two placebo tablets/day)
Trial: 31436886
Drug: Daily naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily naltrexone
Trial: 23369075
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (supervised exercise training twice weekly for eight weeks)
Trial: 23369075
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (weekly telephone support)
Trial: 15291653
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of fluvoxamine (50 mg/day) plus low-dose clozapine (≤ 250 mg/day)
Trial: 15291653
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with clozapine (≤ 600 mg/day)
Trial: 8429114
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg, four times daily)
Trial: 8429114
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg, twice daily)
Trial: 31677703
Drug: Saffron (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (15 mg/d)
Trial: 29247154
Drug: Golimumab (GOL)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GOL) 2 mg/kg administered intravenously at weeks 0, 4, 12, and every 8 weeks
Trial: 29247154
Drug: Golimumab (GOL)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GOL) 2 mg/kg administered intravenously
Trial: 29247154
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) administered intravenously
Trial: 26391697
Drug: Preservative-free fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free fixed-dose combination (FDC) of tafluprost 0.0015% and timolol 0.5%
Trial: 24524229
Drug: Full PopART
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full PopART combination HIV prevention package including annual home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART for those testing HIV-positive
Trial: 15837835
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 or 25 mg orally for 2 months)
Trial: 15837835
Drug: Hydrochlorothiazide (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (dosage not specified, orally for 2 months)
Trial: 2288297
Drug: YN-72 30
RxNorm normalized name: 1-chloro-3-ethyl-1-penten-4-yn-3-ol
DrugBank: Ethchlorvynol (DB00189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: YN-72 30 mg/day
Trial: 2288297
Drug: YN-72 150
RxNorm normalized name: 1-chloro-3-ethyl-1-penten-4-yn-3-ol
DrugBank: Ethchlorvynol (DB00189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: YN-72 150 mg/day
Trial: 2288297
Drug: YN-72 300
RxNorm normalized name: 1-chloro-3-ethyl-1-penten-4-yn-3-ol
DrugBank: Ethchlorvynol (DB00189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: YN-72 300 mg/day
Trial: 27752075
Drug: High-dose folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folinic acid (2 mg kg-1 per day, maximum 50 mg per day; n=23)
Trial: 24649525
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid monitoring with target < 2 mmol/L
Trial: 22727138
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT; V.A.C.® Therapy; KCI USA, Inc.)
Trial: 25972454
Drug: Armodafinil 150
RxNorm normalized name: armodafinil 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 150 mg/day
Trial: 12466165
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.2% twice daily
Trial: 14507154
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment approaches for fixation of mandibular fractures
Trial: 7875025
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Ondansetron 8 mg IV infusion before CDDP, followed by 8 mg tablets in the afternoon and before sleeping on the first day, then 3 tablets of 8 mg daily for the next 3 days.
Trial: 7875025
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Ondansetron 8 mg IV infusion on the first day, followed by the same regimen as Group A.
Trial: 2151197
Drug: Doxazosin 1
RxNorm normalized name: doxazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 1 mg to 16 mg once daily
Trial: 2151197
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg to 100 mg once daily
Trial: 29315129
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block with 30 mL of ropivacaine 0.5% with 1:400,000 epinephrine
Trial: 29315129
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block with active drug and 100 μg of ITM
Trial: 29315129
Drug: Sham adductor
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham adductor canal block with 30 mL of normal saline
Trial: 22386051
Drug: Home-use nonablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-use nonablative fractional laser device (daily treatments during active phase, twice-weekly during maintenance phase)
Trial: 22386051
Drug: Home-use nonablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-use nonablative fractional laser device (twice-weekly treatments during maintenance phase)
Trial: 12942250
Drug: Clotrimazole (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (specific topical antifungal agent)
Trial: 10397513
Drug: Initial periodontal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial periodontal therapy and gingival curettage
Trial: 29145468
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral hygiene instructions only)
Trial: 1387475
Drug: Amlodipine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (single dose)
Trial: 25945764
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium fluoride (SF) 0.11%
Trial: 12828139
Drug: Anesthetic gel
RxNorm normalized name: Topicaine 4% Topical Anesthetic Gel
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Trial: 2547028
Drug: Cisplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (120 mg/m2)
Trial: 2547028
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus etoposide (100 mg/m2 on days 1, 2, and 3)
Trial: 192510
Drug: Practolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (100 mg, three times daily)
Trial: 19328023
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU unfractionated heparin (UFH)
Trial: 19328023
Drug: 2500 IU
RxNorm normalized name: Vitamin A/Vitamin D 2500 IU-270 IU Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2500 IU low molecular weight heparin (LMWH, dalteparin)
Trial: 17366247
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to treatment (took >= 80% of pills)
Trial: 15111980
Drug: Extensive biopsy
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extensive biopsy using intravenous conscious sedation (IVCS) (24 biopsies)
Trial: 15111980
Drug: Standard biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1)
Trial: 11495824
Drug: Clodronate 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1,600 mg/d
Trial: 8071036
Drug: Iopromide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (300 mg I/mL)
Trial: 31494176
Drug: Constipation treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constipation treatments (1 to 2 per day)
Trial: 31333215
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injection (MDI)
Trial: 28039653
Drug: Phrenic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic nerve block (PNB) with 4 ml (30 mg) of 0.75% ropivacaine (group P, n = 28)
Trial: 26068548
Drug: α-keto acids
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-keto acids (KAS) supplementation (0.2 g kg(‐1) body weight each day)
Trial: 19803233
Drug: Acupoint sticking
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint sticking therapy at Shenque (CV 8)
Trial: 19803233
Drug: Routine ward
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine ward treatment of stroke (control group)
Trial: 19358501
Drug: Acupoint sticking
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint sticking therapy
Trial: 17155937
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg orally 1 hour before surgery (group E)
Trial: 17155937
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally 1 hour before surgery (group C)
Trial: 15103536
Drug: Cognitive-behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural treatment programme (18 sessions)
Trial: 10872648
Drug: Teverelix 5
RxNorm normalized name: Teverelix
DrugBank: Teverelix (DB05624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teverelix 5 mg
Trial: 10872648
Drug: Teverelix 3
RxNorm normalized name: Teverelix
DrugBank: Teverelix (DB05624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teverelix 3 mg
Trial: 10872648
Drug: Teverelix 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teverelix 0.5 mg
Trial: 8237139
Drug: Mianserin (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (20-60 mg daily)
Trial: 3925112
Drug: Phenoxymethyl penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl penicillin (250 mg qid) for 10 days
Trial: 28521549
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost 0.1% lotion
Trial: 28521549
Drug: Minoxidil 5%
RxNorm normalized name: MINOXIDIL 5% SOLN,TOP
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minoxidil 5% lotion
Trial: 28521549
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate 0.1% solution
Trial: 28521549
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of latanoprost lotion and betamethasone valerate solution
Trial: 28521549
Drug: Vehicle lotion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle lotion (control group)
Trial: 27010596
Drug: Acupuncture (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (weekly for 5 consecutive weeks)
Trial: 27010596
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (physical therapy, analgesia, and/or antiinflammatory drugs)
Trial: 22118560
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (dalteparin, 5000 IU weight-adjusted dosage) with aspirin 80 mg
Trial: 22118560
Drug: Aspirin 80
RxNorm normalized name: aspirin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 80 mg alone
Trial: 22118560
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin with aspirin
Trial: 2488034
Drug: Topical deoxycytidine
RxNorm normalized name: deoxycytidine
DrugBank: 2'-Deoxycytidine (DB02594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical deoxycytidine 10(‐4) M
Trial: 334230
Drug: Nomifensine (50-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (50-225 mg daily for 2-26 weeks)
Trial: 334230
Drug: Placebo, imipramine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, imipramine, desipramine, viloxazine, nortriptyline, combination of amitriptyline and chlordiazepoxide, diazepam
Trial: 30827001
Drug: NAC followed
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC followed by gastrectomy + adjuvant chemotherapy (Arm B)
Trial: 30827001
Drug: Gastrectomy +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrectomy + adjuvant chemotherapy with S‐1 (Arm A)
Trial: 19338147
Drug: Xiaoliu Baofei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoliu Baofei Pill (XBP) plus chemotherapy
Trial: 15664791
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone replacement therapy
Trial: 11202817
Drug: Iontophoretically administered
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoretically administered lidocaine (anesthetic)
Trial: 9276197
Drug: Bromocriptine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine monotherapy (11 patients)
Trial: 9276197
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with bromocriptine and levodopa (35 patients)
Trial: 8351163
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (0.5 mg) + Sublingual nifedipine (10 mg)
Trial: 8351163
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (0.5 mg)
Trial: 3032470
Drug: CAV1 (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV1 (cyclophosphamide 600 mg m‐2 i.v., adriamycin 50 mg m‐2 i.v., etoposide 500 mg m‐2 p.o. on day 3)
Trial: 3032470
Drug: CAV5 (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV5 (cyclophosphamide and adriamycin as for CAV1, etoposide 500 mg m‐2 given in divided dose over days 3‐7)
Trial: 26142345
Drug: Combination nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination nicotine replacement therapy (cNRT)
Trial: 29389142
Drug: Incentive condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive condition participants received incentives for attending pre‐ and postbirth treatment contacts: $25 for each of 6 prebirth provider visits, $25-40 for each of 4 postbirth home visits, $20 for each of 5 postbirth counseling calls, and $40 for biochemically verified abstinence at Week 1 and 6-month visits.
Trial: 21665048
Drug: New micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New micronized powder formulation of artemisinin (160 or 500 mg)
Trial: 21665048
Drug: Previous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous standard Vietnamese formulation of artemisinin
Trial: 18280375
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel applied during the first postoperative week
Trial: 17065884
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation strategy (tidal volume of 9 ml/kg during two-lung ventilation, reduced to 5 ml/kg during one-lung ventilation; positive end-expiratory pressure 5 cm H2O throughout the operative time)
Trial: 17065884
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation strategy (tidal volume of 9 ml/kg during two-lung and one-lung ventilation; no positive end-expiratory pressure)
Trial: 10357295
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V potassium, 250 mg 3 times daily (n = 239)
Trial: 10357295
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V potassium, 500 mg 2 times daily (n = 239)
Trial: 1920391
Drug: Slow-release carbamazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release carbamazepine (SR) preparation divided into two daily doses
Trial: 1920391
Drug: Conventional carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional carbamazepine (C) preparation divided into three daily doses
Trial: 7038182
Drug: 10% trolamine
RxNorm normalized name: TROLAMINE SALICYLATE 10 g in 100 g TOPICAL CREAM [Hempvana Maximum Strength Pain Relief Cream 10% Trolamine Salicylate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% trolamine salicylate cream
Trial: 31047804
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (5·4 mg/kg or 6·4 mg/kg administered intravenously once every 3 weeks)
Trial: 29052025
Drug: Ultra-low-dose (ULD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose (ULD) technique for CTCA
Trial: 24382118
Drug: Ultra-high molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultra-high molecular weight polyethylene (UHMWPE) implant manufactured by CAM milling
Trial: 16424586
Drug: Correction method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correction method for segmental dose errors
Trial: 12198327
Drug: AIIRA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIIRA with no >L-NMMA
Trial: 12198327
Drug: >L-NMMA co-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >L-NMMA co-infusion
Trial: 30890382
Drug: 1-week 4-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week 4-site ID regimen with purified Vero cell rabies vaccine (PVRV; Verorab®) without rabies immunoglobulin (RIG) (G1)
Trial: 30347561
Drug: Medication of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication of 1 day prior to surgery (30 eyes)
Trial: 30347561
Drug: Medication of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication of 3 days prior to surgery (30 eyes)
Trial: 27501409
Drug: Prototype device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype device for drug administration (scanning required before injection)
Trial: 22689690
Drug: pegylated IFNα2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated IFNα2a weekly for 48 weeks
Trial: 19910118
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention (including Omnibus cognitive-behavioral therapy, relaxation therapy, and biofeedback)
Trial: 19910118
Drug: Self-administered interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered interventions
Trial: 19829284
Drug: Psychological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapies